<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	No antibodies were involved.	n/a
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	No cell lines were involved.	n/a
Primary cultures: Provide species, strain, sex of	No cell lines were involved.	n/a
origin, genetic modification status.		
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	No experimental animals were involved.	n/a
Animal observed in or captured from the field: Provide species, sex and age where possible	No experimental animals were involved.	n/a
Model organisms: Provide Accession number in repository (where relevant) OR RRID	No experimental animals were involved.	n/a
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	No model of plants and microbes were involved.	n/a
Microbes: provide species and strain, unique accession number if available, and source	No model of plants and microbes were involved.	n/a
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Methods/ paragraph 1	
Provide statement confirming informed consent obtained from study participants.	Methods/ paragraph 1	
Report on age and sex for all study participants.	Results/ paragraph 1	

by-step protocols are available.

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	Methods/ paragraph 1	
Laboratory protocol Yes (indicate where provided: section/paragraph)		
Provide DOI or other citation details if detailed step-	Methods/ paragraph 2-4	

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been		
done , or if they were not carried out.		
Sample size determination	Methods/ paragraph 1	
Randomisation	single arm	n/a
Blinding	Open label, single arm	n/a
Inclusion/exclusion criteria	Methods/ paragraph 1	

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Results/ paragraph 2	
Define whether data describe technical or biological replicates	Results/ paragraph 2	

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of	Methods/ paragraph 1	
authority granting ethics approval (IRB or equivalent		
committee(s), provide reference number for		
approval.		
Studies involving experimental animals: State details	No experimental animals were involved.	n/a
of authority granting ethics approval (IRB or		
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if	No specimen and field samples were involved.	n/a
relevant permits obtained, provide details of		
authority approving study; if none were required,		
explain why.		

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,	The study is NOT subject to dual use research of	n/a
state the authority granting approval and reference	concern.	
number for the regulatory approval		

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	No sample or data point from the analysis is excluded, except missing data.	n/a

Statistics	Yes (indicate where provided: section/paragraph)	n/a	
Describe statistical tests used and justify choice of	Methods/ paragraph 5		l
tests.			١

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on	There were no newly created datasets.	n/a
access.		
If data are publicly available, provide accession number in repository or DOI or URL.	No public data was reused.	n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	No public data was reused.	n/a

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential	No newly generated code and software was needed for	n/a
for replicating the main findings of the study:	replicating the main findings of the study.	
State whether the code or software is available.	No newly generated code and software was needed for	n/a
	replicating the main findings of the study.	n/a
If code is publicly available, provide accession number in repository, or DOI or URL.	No newly generated code and software was needed for replicating the main findings of the study.	n/a

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with	·	
the manuscript.		

 $Article\ information: \underline{https://dx.doi.org/10.21037/atm-22-1165}$